cadth 2015 e5 ad panel discussion af
TRANSCRIPT
![Page 1: Cadth 2015 e5 ad panel discussion af](https://reader033.vdocuments.us/reader033/viewer/2022042615/55c47698bb61ebc7228b467b/html5/thumbnails/1.jpg)
Atrial Fibrillation Stroke Prevention with Oral Anticoagulants
Why is there discordance between guideline committees & specialists when the data is based on the same 3 landmark
trials?
![Page 2: Cadth 2015 e5 ad panel discussion af](https://reader033.vdocuments.us/reader033/viewer/2022042615/55c47698bb61ebc7228b467b/html5/thumbnails/2.jpg)
![Page 3: Cadth 2015 e5 ad panel discussion af](https://reader033.vdocuments.us/reader033/viewer/2022042615/55c47698bb61ebc7228b467b/html5/thumbnails/3.jpg)
January 2013
![Page 4: Cadth 2015 e5 ad panel discussion af](https://reader033.vdocuments.us/reader033/viewer/2022042615/55c47698bb61ebc7228b467b/html5/thumbnails/4.jpg)
April 2015
![Page 5: Cadth 2015 e5 ad panel discussion af](https://reader033.vdocuments.us/reader033/viewer/2022042615/55c47698bb61ebc7228b467b/html5/thumbnails/5.jpg)
CCS AF Guidelines
• 2010: • Dabigatran preferred over warfarin
(Conditional Recommendation, High-Quality Evidence).
• 2012: • NOAC preferred over warfarin (note:
apixaban - when approved by Health Canada) (Conditional Recommendation, High-Quality Evidence)
• 2014: • NOAC preferred over warfarin (note:
edoxaban when approved by Health Canada) (Strong Recommendation, High Quality Evidence)
– High value: greater efficacy of dabigatran during a relatively short time of follow-up, lower incidence of intracranial hemorrhage; ease of use
– Less value: long safety experience with warfarin
– High value: greater/similar efficacy, less/same major bleeds, less intracranial bleeds, easier to use
– Less value: long experience with clinical use, antidote, simple/standardized test (i.e. INR)
– High value: greater ease of use, superior/non-inferior, no more/less major bleeding especially less intracranial
– Less value: shorter clinical experience, lack of antidote, lack of simple test for intensity of anticoagulant effect
![Page 6: Cadth 2015 e5 ad panel discussion af](https://reader033.vdocuments.us/reader033/viewer/2022042615/55c47698bb61ebc7228b467b/html5/thumbnails/6.jpg)
CCS AF Guidelines GRADE
![Page 7: Cadth 2015 e5 ad panel discussion af](https://reader033.vdocuments.us/reader033/viewer/2022042615/55c47698bb61ebc7228b467b/html5/thumbnails/7.jpg)
2014 Guidelines
AHA/ASA 2014 Stroke Prevention Guidelines • Prevention of recurrent stroke in patients with non-
valvular AF:• Warfarin or Apixaban (1A)• Dabigatran (IB) • Rivaroxban (IIaB)
AHA/ACC/HRS 2014 AF Guidelines• Prior stroke/TIA or CHA2DS2-VASc score ≥2:
• Warfarin (1A)• Apixaban, dabigatran, rivaroxaban (1B)
![Page 8: Cadth 2015 e5 ad panel discussion af](https://reader033.vdocuments.us/reader033/viewer/2022042615/55c47698bb61ebc7228b467b/html5/thumbnails/8.jpg)
![Page 9: Cadth 2015 e5 ad panel discussion af](https://reader033.vdocuments.us/reader033/viewer/2022042615/55c47698bb61ebc7228b467b/html5/thumbnails/9.jpg)
2014 Guidelines
AHA/ASA 2014 Stroke Prevention Guidelines • Prevention of recurrent stroke in patients with non-
valvular AF:• Warfarin or Apixaban (1A) AVVEROES, ARISTOTLE • Dabigatran (IB) RELY• Rivaroxban (IIaB) ROCKET
AHA/ACC/HRS 2014 AF Guidelines• Prior stroke/TIA or CHA2DS2-VASc score ≥2:
• Warfarin (1A)• Apixaban, dabigatran, rivaroxaban (1B)
• ARISTOTLE, RELY, ROCKET
AVVEROES-Patients deemed unsuitable for VKA - Apixiban 5mg po BID vs ASA
![Page 10: Cadth 2015 e5 ad panel discussion af](https://reader033.vdocuments.us/reader033/viewer/2022042615/55c47698bb61ebc7228b467b/html5/thumbnails/10.jpg)
Committee make-up
![Page 11: Cadth 2015 e5 ad panel discussion af](https://reader033.vdocuments.us/reader033/viewer/2022042615/55c47698bb61ebc7228b467b/html5/thumbnails/11.jpg)
INTERNIST
GASTROENTEROLOGIST
ER PHYSICIAN
HEMATOPATHOLOGIST
HEMATOLOGIST
NEPHROLOGIST
NEUROLOGIST
CARDIOLOGIST
FAMILY PHYSICIAN
![Page 12: Cadth 2015 e5 ad panel discussion af](https://reader033.vdocuments.us/reader033/viewer/2022042615/55c47698bb61ebc7228b467b/html5/thumbnails/12.jpg)
• Why is there discordance between guideline committees & specialists when the data is based on the same 3 landmark trials?• Values influence guideline committees and prescribing.• Patient values need to be considered as well; shared
decision making.• Tailor therapy to individual patients.